Haima Therapeutics is a pre-clinical stage biotechnology company focused on developing bio-inspired therapies for the treatment of bleeding and other blood-related ailments. We have developed a novel, nanoparticle-based synthetic hemostatic technology, called SynthoPlate, that can staunch hemorrhagic bleeding by binding to the site of injury and amplifying your body’s natural clotting mechanisms.
Haima Therapeutics and Case Western Reserve University entered into an option to license agreement in April of 2018. Haima Therapeutics is located at the BioEnterprise incubator centrally located in the University Circle area near Case Western Reserve University, University Hospitals, and the Cleveland Clinic.
Company Details
- Employees
- 14
- Founded
- -
- Address
- 11000 Cedar Ave, Cleveland,ohio,united States
- in****@****ics.com
- Industry
- Biotechnology
- Website
- haimatherapeutics.com
- HQ
- Cleveland, Ohio
Haima Therapeutics Questions
Haima Therapeutics's website is haimatherapeutics.com
Haima Therapeutics's LinkedIn profile is https://www.linkedin.com/company/haima-therapeutics
Haima Therapeutics has
14 employees.
View email and phone details for 14
employees at Haima Therapeutics.
Haima Therapeutics's industry is
Biotechnology
Haima Therapeutics's top competitors are
Copernicus Therapeutics, Inc.,
Convelo Therapeutics, Inc,
Thermalin Inc.,
Diasome Pharmaceuticals, Inc.,
Trailhead Biosystems,
Kalocyte, Inc.,
Allinaire Therapeutics,
Cleveland Diagnostics,
Athersys,
Abeona Therapeutics.
Haima Therapeutics's support email address is info@haimatherapeutics.com
Haima Therapeutics's categories are Biotechnology
Haima Therapeutics's founding year is 2016
